Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology - 1 Jan 2000

Kubelac Paul, Vlad Catalin, Berindan Neagoe Ioana, Irimie Alexandru, Achimas Cadariu Patriciu

Abstract excerpt

PURPOSE: The treatment of ovarian cancer continues to pose a challenge especially through the development of platinum-resistant disease and still has the highest mortality rate among gynecologic cancers. Patients are usually diagnosed with advanced stages where complete cytoreduction and standard platinum-based chemotherapy are the mainstay of treatment. Advances into the molecular underpinnings of DNA damage...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA1 Protein
Share to BRCA2 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease-Free Survival

Share to DNA Damage

Share to Neoadjuvant Therapy

Share to Neoplasm Recurrence, Local

Share to Ovarian Neoplasms

Share to Platinum

Source

Identifiers

PMID: 31646805

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.PMID 31646805Read ↗

Characteristics and outcome of BRCA mutated epithelial ovarian cancer patients in Italy: A retrospective multicenter study (MITO 21).Semantic proximity Read ↗

Frequency of germline mutations in BRCA1 and BRCA2 in ovarian cancer patients and their effect on treatment outcomeSemantic proximity Read ↗

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.Semantic proximity Read ↗

BRCA mutations in the manifestation and treatment of ovarian cancerSemantic proximity Read ↗

Assessing Frequency and Clinical Outcomes of BRCA Mutated Ovarian Cancer in Saudi WomenSemantic proximity Read ↗

Mutational Screening of BRCA1/2 Genes as a Predictive Factor for Therapeutic Response in Epithelial Ovarian Cancer: A Consensus Guide from the Spanish Society of Pathology (SEAP-IAP) and the Spanish Society of Human Genetics (AEGH).Semantic proximity Read ↗

Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancerSemantic proximity Read ↗

Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer.Semantic proximity Read ↗

g BRCA1 and g BRCA2 mutations in specific different domains affect ovarian cancer prognosis: A multicenter retrospective study.Semantic proximity Read ↗

Ovarian cancer treatment in mutation carriers/BRCAness.Semantic proximity Read ↗

Lessons learned from understanding chemotherapy resistance in epithelial tubo-ovarian carcinoma from BRCA1and BRCA2mutation carriers.Semantic proximity Read ↗

Tailoring Ovarian Cancer Treatment: Implications of BRCA1/2 MutationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.